$LLY

Jonsson Patrik sold $7.6M of LLY

Jonsson Patrik (EVP & President, LLY Int'l) sold 6,500 shares of ELI LILLY & Co (LLY) at $1175.10 ($7.64M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jonsson Patrik
Published Aug 18, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not include guidance, trial results, regulatory actions, or deal terms.

02

Market read

Traders may note insider selling, but the 10b5-1 framing and lack of fundamental updates make it low-signal for price action.

03

What to watch

The disclosure does not indicate whether sales were part of broader diversification, tax planning, or option exercises, limiting inference beyond the fact of selling.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP and President Jonsson sold 6,500 shares at $1,175.10 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, unusually large or clustered insider selling can be interpreted as private caution, though this article provides no comparative context.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider sale by EVP and President, LLY International, Patrik Jonsson.

  • Patrik Jonsson

    EVP and President, LLY International, reported an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYHigh

What Is Retatrutide and When Could Weight-Loss Drug Be Publicly Available?

Eli Lilly's phase 3 trial for retatrutide, a weight-loss drug, showed significant weight reduction (17.6% to 25%) and improvements in obesity-related conditions. The drug targets three hormone receptors. Eli Lilly plans to seek FDA approval, but no timeline is set. Unapproved versions of the drug have been linked to deaths, according to reports.

$LLYHigh

Why is Eli Lilly stock rallying today?

Eli Lilly (LLY) stock rose 3.3% to $1,205.24 on pipeline developments and pre-earnings positioning. A clinical trial collaboration with Prelude Therapeutics and a positive cancer drug spending report boosted sentiment. Analysts raised EPS estimates and reiterated Buy ratings. Institutional activity also increased. The S&P 500 and Nasdaq declined, highlighting Lilly's company-specific rally. Q3 2026 earnings are expected on October 29, with consensus EPS at $9.96.

$LLYLow

Eli Lilly has started construction on a $6.5bn plant in Houston to produce Foundayo, its oral GLP-1 treatment for type 2 diabetes and obesity

Eli Lilly has started construction on a $6.5bn plant in Houston to produce Foundayo, its oral GLP-1 treatment for type 2 diabetes and obesity. The facility will create 600 jobs and is part of a $12.5m investment in workforce training. Foundayo is under regulatory review in over 40 countries, with a global rollout planned for 2027. This is the largest active pharmaceutical ingredient project in Texas history, according to Governor Greg Abbott.

$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

$LLYMed

What Is Eli Lilly Stock's Biggest Opportunity?

Eli Lilly (LLY) stock trades at a premium, with growth expectations tied to its weight-loss drug Foundayo. Foundayo is selling in the U.S. and U.K., with 36,000 prescribers and 30% market share of new U.S. patients. Lilly's obesity drugs Mounjaro and Zepbound generated $14.9B of its $23.0B Q2 2026 revenue. Foundayo's expansion and regulatory decisions could drive future growth.